Royalty Pharma plc Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Royalty Pharma plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • Royalty Pharma plc Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was $208M, a 57.9% decline year-over-year.
  • Royalty Pharma plc Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was $859M, a 24.3% decline year-over-year.
  • Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2024 was $859M, a 24.3% decline from 2023.
  • Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2023 was $1.13B, a 2550% increase from 2022.
  • Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2022 was $42.8M, a 93.1% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $859M -$276M -24.3% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-12
2023 $1.13B +$1.09B +2550% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-12
2022 $42.8M -$577M -93.1% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-12
2021 $620M -$355M -36.4% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $975M -$1.37B -58.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-15
2019 $2.35B +$971M +70.5% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $1.38B Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.